

## DAFTAR PUSTAKA

1. Hutagalung M, Cakra IGM, Dhaeng SY. Tinjauan lima besar tumor ganas THT di RSUP Dr Sardjito selama lima tahun (1991-1995). *Kumpulan Naskah Ilmiah Pertemuan Ilmiah Tahunan PERHATI*, Batu, Malang 1996: 952-963.
2. Sastrowijoto Si, Losin K, Setiamika M. Tinjauan retrospektif karsinoma nasofarings di RSUP dr Sardjito selama tiga tahun (1992-1994). *Kumpulan Naskah KONAS XI PERHATI*, Yogyakarta 1995: 1221-1227.
3. Bambang SS. Frekwensi karsinoma nasofarings di bagian THT RSU Dr Kariadi Semarang. *Kumpulan Naskah KONAS II PERHATI*, Jakarta, 1971: 531-545.
4. Sumarman I. Tumor ganas nasofarings di bagian THT RSUP Dr Hasan Sadikin Bandung. *Kumpulan Naskah KONAS II PERHATI*, Jakarta, 1971: 546-567.
5. Sutirto I, Pandi PS. Tumor ganas nasofarings di bagian THT RS Dr Tjipto Mungunkusumo Jakarta. *Kumpulan Naskah KONAS II PERHATI*, Jakarta, 1971: 568-572.
6. Sunarto S. Tumor ganas nasofarings di RS UGM bagian THT 1968-1970. *Kumpulan Naskah KONAS II PERHATI*, Jakarta, 1971: 573-583.
7. Masna PW, dan Suwardana W. Frekwensi tumor ganas di bagian THT RSUP Sanglah Denpasar. *Kumpulan Naskah KONAS V PERHATI*, Semarang, 1977: 803-807.
8. Gosal ID. Insidens minimum tumor ganas nasofarings di Ujungpandang. *Kumpulan Naskah KONAS IV PERHATI*, Semarang: 565-572.
9. Zainuddin MZ. Frekwensi tumor ganas nasofarings di Sumatera Barat. *Kumpulan Naskah KONAS V PERHATI*, Semarang: 599-606.
10. Rivai YA, Syahnawi NP, Muslihuddin A. Tumor ganas nasofarings di bagian THT RSUP/FK UNSRI Palembang. *Kumpulan Naskah KONAS V PERHATI*, Semarang: 573-577.
11. Lutan R, Efendi S, Aboet A. Tinjauan tumor ganas di poliklinik THT RS Dr Pirngadi Medan tahun 1970-1979. *Kumpulan Naskah Ilmiah KONAS VII PERHATI*, Surabaya, 1983: 771-781.
12. Palealu TM, dan Tikoalu MAL. Tumor ganas nasofarings di bagian THT RSU Gunung Wenang/FK Universitas Sam Ratulangi Manado. 1979-1982. *Kumpulan Naskah Ilmiah KONAS VII PERHATI*, Surabaya 1983: 789-796.



UNIVERSITAS  
GADJAH MADA

Kualitas hidup penderita karsinoma nasofaring pasca terapi :: Perbandingan antara yang mendapat radioterapi dengan kombinasi radioterapi ditambah kemoterapi  
RAHMAWAN, Arif, dr. Bambang HW., Sp.THT

Universitas Gadjah Mada, 2004 | Diunduh dari <http://etd.repository.ugm.ac.id/>

13. Sudarmi M. Tumor ganas di bagian THT RS Dr Saiful Anwar Malang (1984-1985). *Kumpulan naskah Ilmiah KONAS VIII PERHATI* Ujungpandang 1986: 293-301.
14. Haryono K, Soediono, Sunaryadi. Tumopr ganas THT di Lab/UPF THT-FK Unair/RSUD Dr Sutomo Surabaya tahun 1981-1985. *Kumpulan Naskah Ilmiah KONAS VIII PERHATI* Ujungpandang, 1986: 302-308.
15. Syafril A. Epidemiologi tumor ganas telinga hidung dan tenggorok. Dalam : Iskandar N, Munir M, Soetjipto D (eds).*Tumor telinga hidung dan tenggorok diagnosis & penatalaksanaannya*. Fakultas Kedokteran Indonesia, Jakarta 1989:1-9.
16. Setiamika M, Kartono, Supadman G. Tumor ganas di bagian THT RSUP Dr Sardjito Yogyakarta tahun 1988-1992. *Kumpulan Naskah PIT PERHATI* Bukittinggi 1993: 444-450.
17. Tarigan S. Beberapa aspek klinik dan pengobatan tumor ganas hidung dan sinus maksila di RSU DADI Ujungpandang tahun 1988-1993. *Kumpulan Naskah Ilmiah PIT PERHATI* Bukittinggi, 1993:531-544.
18. Hayat J, dan Surachman S. Tumor ganas kepala dan leher di RS Hasan Sadikin Bandung periode 1993-1994. *Kumpulan Naskah KONAS XI PERHATI* Yogyakarta 1995: 1433-1438.
19. Douglas K, Siahaan M, Wiratno. Distribusi tumor ganas THT dan kepala leher di RSUP Dr Kariadi Semarang. *Kumpulan Naskah Ilmiah PIT PERHATI*. Batu, Malang 1996: 964-971.
20. Lukmantya. Pola tumor ganas di bagian THT Fakultas Kedokteran Unibraw/ RSUD Dr Saiful Anwar Malang 1 Januari 1994 s/d 30 Juni 1996. *Kumpulan Naskah Ilmiah PIT PERHATI* Batu, Malang 1996: 1067-1073.
21. Tjahyadewi S, Amriyatun. Tumor ganas kepala dan leher di bagian THT RSUP Dr Kariadi Semarang periode 1996-1999. *Makalah bebas pada PIT PERHATI* Palembang 2001.
22. Setiobudi D, dan Kuhuwael FG. Profil penderita karsinoma nasofarings di Sulawesi Selatan Januari 1990-Desember 1999. *Makalah bebas pada PIT PERHATI* Palembang 2001.



- UNIVERSITAS  
GADJAH MADA
23. Mulyarjo. Diagnosis dan penatalaksanaan karsinoma nasofarings. Dalam: Mulyarjo *et al.* (eds) *Naskah lengkap pendidikan kedokteran berkelanjutan III Ilmu Penyakit THT KL "Perekembangan terkini diagnosis dan penatalaksanaan tumor ganas THT-KL"* Lab Ilmu Penyakit THT FK Unair/RSUD Soetomo Surabaya 2002: 48-48.
  24. Soetjipto D. Karsinoma nasofarings. Dalam : Iskandar N, Munir M, Soetjipto D (eds). *Tumor telinga hidung dan tenggorok diagnosis & penatalaksanaannya*. Fakultas Kedokteran Indonesia , Jakarta 1989: 71-84.
  25. Susilo N; dan Wiratno. Karsinoma nasofaring di SMF THT RSUP Dr Kariadi Semarang tahun 1990-1994. *Kumpulan Naskah KONAS XI PERHATI*, Yogyakarta 1995: 1229-1237.
  26. Prasad U, Wahid MIA, Jalaludin MA, Abdullah BJJ, Paramsothy M, Abdul-Kareem S. Long-term survival of nasopharyngeal carcinoma patients treated with adjuvant chemotherapy subsequent to conventional radical radiotherapy. *Int J Radiat Oncol Bio Phys* 2002; 53: 648-655.
  27. Lin J-C, and Jan J-S. Locally advanced nasopharyngeal cancer: long-term outcomes of radiation therapy. *Radiology* 1999; 211: 513-518.
  28. Teo PML, Yu P, Lee WY *et al*. Significant prognosticator after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. *Int J Radiat Oncol Bio Phys* 1996; 36:291-304.
  29. Wei WI, and Sham JST. Present status of management of nasopharyngeal carcinoma. *Expert Rev Anticancer Ther* 2001; 1: 134-141.
  30. Slevin MR, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patients? *Br J Cancer* 1988; 57: 109-112.
  31. Trott A. Toxicity in head and neck cancer: a review of trends and issues. *Int J Radiat Oncol Biol Phys* 2000; 47: 1-12.
  32. Ware JE, and Sherbourne CD. The MOS 36 item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992; 30: 473-483.
  33. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. *J Clin Oncol* 1984; 2: 472-483.
  34. Bajuadji HS, dan Suprawimbarti. Uji kelayakan kuesioner SF-36 dan studi respon masyarakat kelompok sehat-sakit wilayah Magelang dan Yogyakarta. *Tesis. Program Pascasarjana Universitas Gadjah Mada Yogyakarta* 1998.

35. Majangsari RGD. Hubungan anemia dan kualitas hidup ibu hamil dengan bayi berat lahir rendah pada beberapa rumah sakit di Bandung. *Tesis. Program Pascasarjana Universitas Gadjah Mada Yogyakarta* 2001.
36. Karnofsky DA, and Burchenal DH: Clinical evaluation of chemotherapeutic agents in cancer. In: McLeod CM (editor): *Evaluation of Chemotherapeutic Agents*. New York, Columbia University Press, 1949.
37. List MA, Ritter-Sterr CA, Lansky SB. A performance status scale for head and neck cancer patients. *Cancer* 1990; 66: 564-569.
38. Celli DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bobomi A, et al. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. *J Clin Oncol* 1993; 11:570-579.
39. Bjordal K, and Kassa S. Psychometric validation of the EORTC core of quality of life questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. *Acta Oncol* 1992; 31: 311-321.
40. Hassan SJ, and Weymuller Jr EA. Assessment of quality of life in head and neck cancer patients. *Head Neck* 1993; 15: 485-496.
41. Weymuller EA,Jr, Yueh B, Deleyiannis FWB., Kuntz AI, Alsarraf R, Coltrera MD., Quality of life in patients with head and neck cancer. Lessons learned from 549 prospectively evaluated patients. *Arch Otolaryngol Head Neck Surg* 2000; 126: 329-335.
42. Hammerlid E, and Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. *Br J Cancer* 2001; 84: 149-156.
43. Epstein JB, Emerton S, Kolbinson DA, Le ND, Phillips N, Stevenson-Moore P, et al. Quality of life and oral function following radiotherapy for head and neck cancer. *Head Neck* 1999; 21: 1-11.
44. Fang F-M, Chiu H-C, Kuo W-R, et al. Health-related quality of life for nasopharyngeal carcinoma patients with cancer-free survival after treatment. *Int J Radiat Oncol Bio Phys* 2002; 53: 959-968.
45. Talmi YP, Horowitz Z, Bedrin L, Wolf M, Chaushu G, Kronenberg J, Pfeffer MR. Quality of life of nasopharyngeal carcinoma patients. *Cancer*. 2002 Feb 15;94(4):1012-7.

46. Yu CL, Fielding R, Chan CL, Sham JS. Chinese nasopharyngeal carcinoma patients treated with radiotherapy: association between satisfaction with information provided and quality of life. *Cancer*. 2001 Oct 15;92(8):2126-35.
47. Chia KS, and Lee HP. Epidemiologi. In: Chong VHF and Tsao SY eds. *Nasopharyngeal carcinoma*. Armour Publishing Pte Ltd, Singapore 1997: 1-5.
48. Dickson RI, and Flores AD. Nasopharyngeal carcinoma: an evaluation of 134 patients treated between 1971-1980. *Laryngoscope* 1985; 95: 276-283.
49. Armstrong RW, Armstrong MJ, Lye MS. Social impact of nasopharyngeal carcinoma on chinese households in Selangor, Malaysia. *Singapore Med J* 2000; 41: 582-587.
50. Wei WI, and Sham JST. Cancer of the nasopharynx. In: Myers EN, Suen JY eds. *Cancer of the head and neck*. Third edition. WB Saunders company. Philadelphia-London-Toronto-Montreal-Sydney-Tokyo 1996: 277-293.
51. Wang CC. *Radiation therapy for head and neck neoplasm*. A John Wileys & Sons, Inc Publition. New York-Chichester-Brisbane-Toronto-Singapore-Weinheim 1997:257-280.
52. Shanmugaratnam K, Chan SH, de-Thé G, et al. Histopathology of nasopharyngeal carcinoma. Correlations with epidemiology, survival rates and other biological characteristics. *Cancer* 1979, 44: 1029-1044.
53. Hadi W, dan Kusuma H. Aspek klinis dan histopatologi karsinoma nasofarings (tinjauan 129 kasus). *Kumpulan Naskah Ilmiah KONAS XII PERHATI*, Semarang 1999: 1001-1007.
54. Lusy ILP, Samodra E, Upang W. Pola epidemiologi klinis karsinoma nasofarings di poliklinik THT RSUP Dr Sardjito th. 2000. *Makalah bebas pada PIT PERHATI* Palembang 2001.
55. American Joint of Committee on Cancer. *Manual for Staging of Cancer*, eds 4<sup>th</sup>, Philadelphia, JB Lippincott, 1998.
56. Indudharan R, Valuyetham KA, Kannan T, Sidek DS. Nasopharyngeal carcinoma: clinical trends. *J Laryngol Otol* 1997; 111: 724-729.
57. Kamal MF, and Sammarai SM. Presentation and epidemiology of nasopharyngeal carcinoma in Jordan. *J Laryngol Otol* 1999; 113: 422-426.
58. Lee AWM, Foo W, Law SCK et al. Nasopharyngeal carcinoma-presenting symptoms and duration before diagnosis. *HKMJ* 1997; 3: 355-361.

59. Skinner DW, van Hasselt CA, Tsao SY. Nasopharyngeal carcinoma: modes of presentation. *Ann Otol Rhinol Laryngol* 1991; 100: 544-551.
60. Lee AWM, Ko WM, Foo W, Choi P, Tung Y, Sham J, et al. Nasopharyngeal carcinoma-time lapse before diagnosis and treatment. *HKMJ* 1998; 4: 132-136.
61. Bentzen JKD, Ockelmann HH, Albeck H, Olsen J, Hansen HS. Nasopharyngeal carcinoma treated at the Finsen isntitute, Copenhagen 1965-1985: survival and some prognostic factors. *Laryngoscope* 1991; 101: 635-642.
62. Muyassaroh, Samsudin, Soetedjo. Kelainan neurologik pada karsinoma nasofaring di SMF Kesehatan THT RSUP Dr Kariadi Semarang tahun 1996-1998. *Kumpulan Naskah KONAS XII PERHATI*, Semarang: 1132-1140.
63. Tjokronagoro M. Randomized control trial of accelerated hyperfractionation radiotherapy versus conventional radiotherapy for the treatment of local advance undifferentiated nasopharyngeal carcinoma. *B I Ked* 2000; 32: 263-269.
64. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal carcinoma. *Ann Oncol* 2002; 13: 1007-1015.
65. Chan ATC, Teo PML, Leung TWT, Leung SF, Lee WY, Yeo W, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 1995; 33:569-577.
66. International Nasopharynx Cancer Study Group. Preliminary results of randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy versus radiotherapy alone in stage IV ( $\geq N2, M0$ ) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. *Int J Radiat Oncol Biol Phys* 1996; 35: 463-469.
67. Chua DTT, Sham JST, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, et al. Preliminary report of the Asian Oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. *Cancer* 1998; 83: 2270-2283.
68. Cheng SH, Jian JJ-M, Tsai SCY, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. *Int J Radiat Oncol Biol Phys* 2000; 48: 1323-1330.



- UNIVERSITAS  
GADJAH MADA
69. Cheng SH, Yen KL, Jian JJ-M, Tsai SYC, Chu NM, Leu SY *et al.* Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. *Int J Radiat Oncol Biol Phys* 2001; 50: 717-726.
  70. Al-Sarraf M, LeBlanc M, Giri S, Fu KK, Cooper J, Vuong T, *et al.* Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer. Phase III randomized intergroup study 0099. *J Clin Oncol* 1998; 16: 1310-1317.
  71. Lee AWM, Sze WM, Yau Tszy-K, Yeung RMW, Chappell, Fowler JF. Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity. *Radiother Oncol* 2001; 58: 121-130.
  72. Chen YP, Tsang NM, Tseng CK, Lin SY. Causes of interruption of radiotherapy in nasopharyngeal carcinoma patients in Taiwan. *Jpn J Clin Oncol* 2000; 30: 230-234.
  73. World Health Organization. The first ten years of the World Health Organization. Geneva : WHO, 1958.
  74. Departemen Kesehatan RI. Undang-Undang Republik Indonesia Nomor 23 Tahun 1992 tentang Kesehatan.
  75. Testa MA, and Simonson DC. Assessment of quality of life outcomes. *N Engl J Med* 1996; 334: 835-840.
  76. Calman KC. Quality of life in cancer patients – a hypothesis. *J Med Ethics* 1984; 10: 124-127.
  77. Ware JE. Conceptualizing disease impact and treatment outcomes. *Cancer* 1984; 53: 2316-2323.
  78. Kirshner B, and Guyatt GH. A methodologic framework for assessing health indices. *J Chron Dis* 1985; 38: 27-36.
  79. Guyatt GH, and Jaeschke R. Measurement in clinical trials: choosing the appropriate Approach. In: Spilker (editor) *Quality of life assessment in clinical trials*. Raven Press, Ltd. New York 1990.

80. Deleyiannis FW-B, and Weymuller EA, Jr., Quality of life in patients with head and neck cancer. Dalam: Myers EN, Suen JY eds. *Cancer of the head and neck*. Third edition. WB Saunders company. Philadelphia-London-Toronto-Montreal-Sydney-Tokyo 1996: 904-916.
81. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Ann Intern Med* 1993; 118: 622-629.
82. Streiner DL, and Norman GR. Health measurement scales. A practical guide to their development and use. Oxford University Press 1989.
83. Spitzer WO, Dobson AJ, Hall J, Chestermen E, Levi J, Sheperd R, *et al.* Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. *J Chron Dis* 1981; 34: 585-597.
84. Bergner M, Bobbitt RA, Carter WB, *et al.* The Sickness Impact Profile: development and final revision of a health status measure. *Med Care* 1981; 19: 787-805.
85. Hunt SM, McKenna SP, McEwen J, *et al.* The Nottingham Health Profile: subjective health status and medical consultations. *Soc Sci Med* 1981; 15: 221-229.
86. Zubrod CG, Schneiderman M, Frei E, *et al.* Appraisal of methods for study of chemotherapy in man. *J Chron Dis* 1960; 11 : 7.
87. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, *et al.* The European Organization for Research and Treatment of Cancer QLQ-C30:a quality of life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; 85: 373-374.
88. Browman GP, Levine MN, Hodson DI, Sathya J, Russell P, Skingley P. *et al.* The head and neck radiotherapy questionnaire: a morbidity/quality of life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. *J Clin Oncol* 1993; 11: 863-872.
89. Sehlen S, Hollenhorst H, Lenk M, Schymura B, Herschbach P, Aydemir U. *et al.* Only sociodemographic variables predict quality of lie after radiotherapy in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2002; 52: 779-783.
90. Trott A, Johnson DJ, Gwede C, Casey L, Sauder B, Cantor A, *et al.*, Development of a head and neck companion module for the quality of life radiation therapy instrument (QOL-RTI). *Int J Radiat Oncol Bio Phys* 2002; 42: 257-261.



UNIVERSITAS  
GADJAH MADA

Kualitas hidup penderita karsinoma nasofaring pasca terapi :: Perbandingan antara yang mendapat radioterapi dengan kombinasi radioterapi ditambah kemoterapi  
RAHMAWAN, Arif, dr. Bambang HW., Sp.THT  
Universitas Gadjah Mada, 2004 | Diunduh dari <http://etd.repository.ugm.ac.id/>

91. Murry T, Madasu R, Martin A, Robbins KT. Acute and chronic in swallowing and quality of life following intraarterial chemoradiation for organ preservation in patients with advanced head and neck cancer. *Head Neck* 1998; 20: 31-37.
92. Gliklich RE, Goldsmith TA, Funk GF. Are head and neck specific quality of life measures necessary? *Head Neck* 1997; 19: 474-480.
93. McDowell I, and Newell C. *Measuring health. A guide to rating scales and questionnaires*. New York-Oxford. Oxford University Press. 1996.
94. Brazier JE, Harper R, Jones NMB, O'Cathain A, Thomas KJ, Usherwood T, et al. validating the SF-36 Health Survey questionnaire: new outcome measure for primary care. *BMJ* 1992; 305: 160-164.
95. Katz JN, Larson MG, Phillips CB et al. Comparative measurement sensitivity of short and longer health status instruments. *Med Care* 1992; 30: 917-925.
96. Brazier J, Jones N, Kind P. testing the validity of the Eurqol and comparing it with SF-36 Health Survey questionnaire. *Qual Life Res* 1993; 2: 169-180.
97. Ware JE, Snow KK, Kosinski M, Gandek B., *SF-36 Health Survey: manual and interpretation guide*. Boston, Massachusetts: The Health Institute, New England Medical centre, 1993.
98. Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C et al. Canadian normative data for the SF-36 health survey. *CMAJ* 2000; 163: 265-271.
99. Wingo PA, Higgins JE, Rubin GL, Zahniser SC. *An epidemiologic approach to reproductive health.*, chapter 9. Cohort Studies. WHO Geneva 1991: 351-388.
100. Sastroasmoro S, dan Ismael S. *Dasar-dasar metodologi penelitian klinis*. Binarupa Aksara 1995.
101. Lameshow S, Hosmer Jr, DW, Klar J, Lwanga SK. *Besar sampel dalam penelitian kesehatan* (terjemahan). Gadjah Mada University Press. Yogyakarta 1990.
102. Wagener DJTH. Penelitian klinik eksperimental dalam onkologi. Dalam: Arjono dkk. (eds): *Onkologi*. Panitia Kanker RSUP Dr. Sardjito Yogyakarta 1999: 183-182.

103. McHorney CA, Ware JE, Coulter AE, The MOS 36-item short form health survey (SF-36), II: Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care* 1993; 31: 247-263.
104. McHorney CA, Ware JE, Lu JFR, Sherbourne CD. The MOS 36-item short form health survey (SF-36), III: Tests data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care* 1994; 32: 40-66.
105. Hammerlid E, Wirblad B, Sandin C, Mercke C, Edström S, Kaasa S, et al. Malnutrition and food intake in relation to quality of life in head and neck cancer patients. *Head Neck* 1999; 20: 540-548.
106. Sabbatini P. The relationship between anemia and quality of life in cancer patients. *The Oncologist* 2000; 5 (suppl 2): 19-23.